GHRS

GH ResearchB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$36.00

+47.4% vs current

Most likely

Base case

45%

Probability

Target price

$24.00

-1.8% vs current

B-

Bear case

30%

Probability

Target price

$11.00

-55.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-28

AI commentary

Sentiment is positive but mostly monitoring-style: recent headline buzz rose after April 2026 psychedelic-policy news, while the stronger company-specific supports are the January FDA hold removal and March peer-reviewed publication. The deterministic packet still shows very weak evidence quality and very high uncertainty, so this remains a low-conviction biotech milestone setup rather than a confirmed re-rating.

RankAlpha Sentiment Codex - 2026-04-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPeer-reviewed Phase 2b publication may support scientific credibility but is mostly a digestion catalystHigh impact

GH Research said Phase 2b GH001 results in TRD were published in JAMA Psychiatry on March 25, 2026, alongside a new finding that efficacy was independent of prior antidepressant treatment failures, which can help external validation but does not by itself remove execution risk [#PR-2026-03-25].

2026-09-30catalystBalance sheet and proprietary device work extend runway for the lead programHigh impact

GH Research reported $280.7 million of cash, cash equivalents and marketable securities as of December 31, 2025 and said its Phase 1 trial of the proprietary aerosol delivery device is intended to support the global GH001 program, which helps funding and platform continuity but still needs execution [#PR-2026-03-05].

2026-12-31eventFDA hold removal and targeted 2026 Phase 3 start are the main value inflectionHigh impact

The company announced on January 5, 2026 that the FDA lifted the GH001 clinical hold, clearing U.S. clinical investigation and leaving FDA alignment on a global Phase 3 program and actual trial initiation in 2026 as the key next step [#PR-2026-01-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-28 • Updated nightlySource: Internal modelMethodology